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ABSTRACT
Innate immunity, one of two arms of the immune system, can provide more 
rapid defense mechanisms than adaptive immunity in human immune defense 
systems. The innate immune system recognizes invading pathogens by binding a 
variety of ligands to the family of Toll-like receptors (TLRs) which play important 
roles in linking innate and adaptive immunities in host immune defense.
Direct application of natural TLR ligands in the pharmaceutical industry is 
evidently limited due to their complicated components and high toxicity, and 
hence synthetic TLR ligands have emerged as competitive therapeutic agents 
involved in various diseases including infection, inflammation and cancers.
Alginates are unbranched and non-repeating linear polysaccharides comprising 
1,4-linked (3-D-mannuronic acid (M) and the C-5-epimer a-L-guluronic acid (G) 
with highly variable composition and sequential structure. They act as strong 
immune stimulants mediated by TLR2 and TLR4. p-1,4-D-mannuronic acid 
neoglycolipids (1 and 2), in this thesis, have been designed as potential ligands for 
TLR 2/4. The chemical synthesis of 1 and 2 have been described. Through 
diastereoselective p-glycosylation of the 4,6-0-benzylidene protected a- 
thiomannoside donor 9 with glycosylation acceptors 6, 12 and 18 respectively, 
followed by a series of deprotection and protection steps, the protocol successfully 
provides p-l,4-<i/- and tr/-D-mannosides. Finally, the TEMPO/BAIB mediated 
oxidation and global hydrogenlization steps lead us to the target molecules 1 and 2:
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Historically, the name carbohydrates came from the description of 
compounds with formula Cn(H20)n "carbon-hydrates". Today, the word 
"carbohydrate" no longer has limitations in "carbon & hydrates" because 
many carbohydrates are devoid of specific hydroxyl groups or have amino 
groups or other functional groups.
Carbohydrates were traditionally viewed as energy-storage materials 
(in the form of monosaccharides and polysaccharides such as starch), 
structural materials (the polysaccharides cellulose in plants and chitin in the 
exoskeletons of insects) and primary metabolites that were produced in 
photosynthesis and were destined for further conversion in nature.
Compared with two of three major polymers responsible for the storage 
of information and signal transduction processes in biological systems; 
nucleic acids and proteins, carbohydrates are the most complex and 
diverse class of biopolymers commonly found in nature as glycoconjugates. 
A wide array of available monosaccharides and diversified stereochemical 
linkages between each pair of carbohydrates results in tremendous 
complexity. Furthermore, the chain length of the oligosaccharides can also 
vary widely from monosaccharides up to branched oligosaccharides with 
more than 30 building blocks, or in the case of polysaccharides to several 
thousand building blocks.
There are ten monosaccharides (Fig. 1.1) found in mammalian 
systems which are covalently linked to other types of molecules at the 
anomeric position, and are given the generic name, glycoconjugates.^







OH OH OH OH
D-Glc D-Gal D-Man
















H O -V ^ ^ A .
OH OH
OH






Fig. 1.1 Monosaccharides found in mammalian glycoconjugates
1.1.2. Biological Roles of Carbohydrates
Cells can recognize one another through pairs of structures on their 
surfaces such that a structure on one cell carries encoded biological 
information that the structure on the other cell can decipher. Nature's choice 
of carbohydrates as information carriers is very clever because 
oligosaccharides are polyols and a large diversity of structures is possible 
from a small number of monosaccharides.
The biological roles of oligosaccharides include functions such as 
structural, protective and stablizing roles for polypeptides and proteins, 
specific receptors for noxious agents, masking and decoys for protection 
from microorganisms and antibodies, specific receptors for symbiotic 
functions, on-off and tuning functions for the biological activity of proteins.
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intercellular trafficking functions, regulating the clearance or turnover of 
proteins and whole cells, hormonal action, and cell-cell and cell-matrix 
recognition.^
Among these biological roles of oligosaccharides, the binding of 
bacteria, viruses, fungi, parasites and toxins to carbohydrate receptors are 
not beneficial to human.^ Binding of pathogens to glycoconjugates often 
causes various inflammation, cancer or infection.
In addition, oligosaccharides are present as glycoconjugates in all cell 
walls mediating a variety of events such as inflammation, cell-cell 
recognition, immunological response, metastasis, and fertilization. 
Alterations in cell surface oligosaccharides have been found to be 
associated with many pathological conditions such as cancer, the growth of 
tumors and tuberculosis.
1.1.3. Glycolipids
The carbohydrate part of glycoconjugates is called the glycan and the 
non-carbohydrate part is called the aglycon. When the aglycon is a lipid, it 
is termed a glycolipid: the lipid part functions to anchor the sugar residue in 
the lipid bi-layer of eukaryotic cell membranes.
Glycolipids have been commonly viewed as carbohydrate-attached 
lipids. Their role is to provide energy and also serve as markers for cellular 
recognition. They extend from the lipid bilayer into the aqueous 
environment outside the cell where they act as a recognition site for specific 
chemicals and help to maintain the stability of the membrane. In an 
aqueous milieu, the polar heads of lipids tend to orient toward the polar, 
aqueous environment, while the hydrophobic tails tend to minimize their 
contact with water. The lipophilic tails of lipids (U) tend to cluster together, 
forming a lipid bi-layer (1) or a micelle (2) (Fig. 1.2). The polar heads (P) 
face the aqueous environment. The spherical micelles form at given points
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
above the critical micelle concentration in a polar milieu, while the lipids 
form a single layer on the liquid surface and are (sparingly) dispersed in the 
solution below the critical micelle concentration in a polar environment.
( 1 )
n I f
Fig. 1.2 Two orientations of lipids as (1) bilayer (2) micelle
Using both their hydrophilic head and hydrophobic tail, glycolipids can 
readily and spontaneously form a liposome structure in an aqueous 
environment (Fig. 1.3). Novel advances in liposomal formulation 
technology have resulted in combination of drugs or compounds in unique 
and stable liposomes. The liposomal formulation overcomes the problem of 
delivery of difficult-to formulate and water-insoluble drugs to intracellular 
targets to treat a variety of disease states. Through their adsorption, 
endocytosis, fusion of the cell with a vesicle and lipid exchange, liposome 
systems'* as the popular drug delivery platform have various desired 
properties, including:
• Being nontoxic and bio-degradable.
• Being modified to release drugs slowly resulting in prolonged 
exposure and hence increasing the specific therapeutic efficacy of 
drugs.
• As a potential source of nutrition recognized by cancer cells and 
eventually destroying them.
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Providing an environment enclosed both hydrophilic and 
hydrophobic molecules.
Fig. 1.3 Schematic representation of a liposome 
(Image courtesy of Neopharm. Inc.)
1.1.4. Roles of Carbohydrates in Drug Design
An effective drug should first be a target-specific one which can be 
expected by its users to have high efficiency and having few, if any, side 
effects. This type of target specificity also means recognition when 
carbohydrates come in. A huge number of drugs contain carbohydrates as 
components in their molecular structure while other drugs, lacking 
carbohydrates covalently bound to their molecules, can also be guided by 
them. It has been widely realized that carbohydrates’ value is to provide a 
guidance mechanism for sick cells and to enable drugs to arrive there with 
precision and act properly. As they should be, carbohydrates also provide a 
defense mechanism for sick or deadly cells, preventing drugs to act 
effectively.
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1.2. Alginates
1.2.1. Structure of Alginate
Chemically, alginate is an unbranched, non-repeating and linear 
polysaccharide with homopolymeric blocks of (1-4)-linked p-D-mannuronic 
acid (M) and its 0-5 epimer a-L-guluronic acid (G) residues, respectively, 
covalently linked together in different sequences or blocks (Fig. 1.4). The 
monomers can appear in homopolymeric blocks of consecutive G-residues 
(G-blocks), consecutive M-residues (M-blocks), alternating M and 
G-residues (MG-blocks) or randomly organized blocks. The relative amount 
of each block-type varies depending upon the different alginates sources 
from which they are isolated. Alginates from bacteria also display a certain 
















Fig. 1.4 Structure of poly-D-mannuronic acid, 
poly-L-guluronic acid, poly-GM and alginate
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1.2.2. Natural Occurrence of Alginates
In nature, alginate Is mainly found as the structural substance of 
marine brown seaweed in which alginate exists as the most abundant 
polysaccharide comprising up to 40% of their dry weight.® In addition, 
alginate has been found as a mucoid exopolysaccharide (MEP), so-called 
mucoid strain, produced by bacteria such as Pseudomonas aeruginosa, 
which is the predominant bacterial pathogen in chronic pulmonary infection 
of cystic fibrosis (CF) patients. Furthermore, alginate also exists as a 
capsular polysaccharide for the bacteria Azotobactor vinelandii and 
Azotobacter chroococcum^'^^ The main difference between algal and 
bacterial alginate is that the mannuronate residues of bacterial rather than 
those of the seaweed polymers are 0-acetylated to a variable extent at 
positions 0-2 and 0-3.^^
1.2.3. Industrial Uses of Alginates
The block structure and extent of 0-acetylation determine the 
physicochemical properties of different alginates.
MG-blocks form the most flexible chains and are more soluble at low 
pH than the other two block-types.^® Alginates containing polyguluronate 
can form rigid gels in the presence of divalent cations (e.g.Ca^" ,̂ Bâ "̂ , Sr̂ "̂ ), 
whereas an absence of poly-G, in P. aeruginosa but not in vinelandii, 
produces relatively soft acidic gels at low pH in the presence of Câ "̂ . The 
stability of the gel is mostly dependent on the content of G-blocks. ®' 
Moreover, extensive 0-acetylation of bacterial alginates increases the 
water-binding capacity of the polysaccharide, which may enhance bacterial 
survival under desiccating conditions.
Based on the characteristics above, alginates have various industrial 
uses as viscosifiers, stabilizers and gel-forming, film-forming or
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
water-binding agents ranging from textile printing, ceramics manufacturing, 
welding rods production and water treatment, to custard creams and 
restructured food production, as well as stabilizers and thickeners utilized in 
the variety of beverage, ice-creams, emulsions and sauces/® In addition, 
the pharmaceutical industry also uses alginates as wound dressings, dental 
impression materials and tablet binders or disintegrants. ®̂
Furthermore, alginates have been biotechnologically utilized for the 
semi-permeable encapsulation of cells and enzymes. Through droplets of a 
mixture of cells or enzymes and Na-alginate into a solution with a 
gel-forming cation (Ca^*), the gel-beads with a high amount of poly-G 
blocks exhibit high porosity, low shrinkage during gel-formation and low 
swelling after drying. ® Hence, entrapment within spheres of a calcium 
alginate gel as a useful technique for immobilization of living cells has been 
wildly recognized.
1.2.4. Roles of Alginates in Pseudomonas Aeruginosa
Pseudomonas aeruginosa is a Gram-negative, aerobic, rod-shaped 
bacterium with unipolar mot i l i ty .An opportunistic human pathogen, P 
aeruginosa is also an opportunistic pathogen of plants.^® As an 
opportunistic pathogen of immunocompromised individuals, P. aeruginosa 
typically infects the pulmonary tract, urinary tract, burns, wounds, and also 
causes blood infections.^® One in ten hospital-acquired infections are from 
Pseudomonas. Cystic fibrosis patients are also predisposed to P. 
aeruginosa infection of the lungs.
Alginates, being the essential constituent in P. aeruginosa, have been 
found to have inherent and excellent performance in immune modulating 
and anti-tumor activities. It has been reported that alginates have the ability 
to form biofilms, cause chronic infection in the lungs of cystic fibrosis 
patients and act as a barrier to protect the infected cells from humoral and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
cellular host defence systems as well as from the action of antibiotics/®
Co-administration of antibodies with alginate lyase, which degrades 
the exopolysaccharide produced by mucoid strains of P. aeruginosa, might 
benefit CF patients by increasing the efficacy of antibiotic in the respiratory 
tract/^ The MEP-KLH (Keyhole Limpet Hemocyanin) conjugate vaccine, 
comes from using SMCC (Sulfosuccinimidyl 4-[/V-maleimidomethyl] 
cyclohexane-1 -carboxylate) as a linker and it can enhance high titers of 
MEP-specific opsonic antibodies in mice and rabbits/^
The alginate capsule produced by the human pathogen P. aeruginosa, 
mainly composed of 1-4-linked (3-D-mannuronic acid polymers (poly-M). 
They have been found to immunostimulate strongly and share with 
lipopolysaccharide (LPS) the ability of stimulating human monocytes 
mediated by TLR2/4 to produce the cytokines tumor necrosis factor alpha 
(TNF-a) and interleukins (IL-1 and IL-6), through binding to membrane 
CD14.^®
1.2.5. Biosynthesis o f Alginates
The biosynthesis of alginate was first illucidated by Lin and Hassid in 
1975 involved in detecting the enzyme activities necessary for the 
synthesis of mannuronan in a cell-free system from fucus gardineriiP 
A.vinelandii and Paeruginosa have been found to have the same 
biosynthesis pathway as follows; D-fructose-6-phosphate is firstly 
converted to sugar nucleotide GDP-D-mannose and then oxidized to 
GDP-D-mannuronic acid followed by being polymerized to mannuronan. 
The mannuronan can be further modified by an acetyl transferase and 
epimerized by a mannuronan C-5-epimerase to L-guluronic acid (Fig. 
1.5).
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D-Fructose-6-phosphate










I  Lyase (AlgL)
I
I Acetylase (Algl, AlgJ, AlgF) 
t
Alginate
Fig. 1.5 Biosynthesis pathway of alginate
1.3. Toll-like Receptors
1.3.1. Discovery of TLR
The name TOLL originally came from a cell surface receptor governing 
dorsal/ventral orientation in the early drosophila larvae which was also 
found later to play a critical role in antifungal defense together with other 
antimicrobial peptides/® In the 1990s, the first mammalian proteins 
structurally similar to Drosophila TOLL were discovered and later named 
human Toll-like receptor (TLR) 1 and 4. It has been revealed that 10 human 
and 9 murine transmembrane proteins belong to the mammalian TLR
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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family/^
Toll-like receptors (TLRs) are single-pass transmembrane integral 
membrane proteins (IMP) that span from the internal to the external surface 
of the biological membrane or lipid bilayer in which they are embedded/®
TOLL and TLR family proteins are characterized by the presentation of 
an extracellular domain with leucine-rich repeats and an intracytoplasmic 
region containing a TOLL/interleukin-1 receptor homology (TIR) domain. 
The TOLL/interleukin-1 receptor homology (TIR) domain is very important 
to both Drosophilia TOLL and mammalian TLR signaling, indicating that 
both of them share homologous signaling components. In fact, the 
homologous signaling components have been actually described as two 
systems: mammalian TLR and Drosophila TOLL, for each signaling step.^®
1.3.2. Roles of PAMP and TLR in Host Defense
Pathogen-associated molecular patterns (PAMP), referring to the 
recognition of components on the pathogen that are not normally found in the 
host, have been described as a critical element in the initiation of an innate 
immune response against various pathogens.
Toll-like receptors have a crucial role in the detection of microbial 
infection in mammals and insects. In mammals, these receptors have 
evolved to recognize conserved products unique to microbial metabolism.^® 
This specificity allows the Toll proteins to detect the presence of infection 
and to induce activation of inflammatory and antimicrobial innate immune 
responses.
TLRs can recognize pathogens and activate immune cell responses as 
a key part of the innate immune system and hence appear as recognition 
receptors with evolutionary conserved patterns. These receptors can be 
utilized to distinguish between self and non-self by adhesion of 
pathogen-related molecular models with no obvious structure similarity in 
host immune defense.^® TLR2 and TLR4 have been found to mediate the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cytokine production induced by alginate polymers and alginate 
oligosaccharides in human immune system.
In vertebrates, TLRs can help activate the adaptive immune system, 
linking innate and acquired immune responses. They function as a dimer 
and may depend on other co-receptors for full ligand sensitivity, such as in 
the case of TLR4's recognition of lipopolysaccharides (LPS), which requires 
MD-2, CD14 and LPS Binding Protein (LBP).^^
Activation of TLRs and cascade signaling pathways lead to the 
expression of pro- and anti-inflammatory mediators which have great 
impact on human physiology.
The particular mechanism^^ has been described (Fig. 1.6) that, after 
infection, antigen-presenting cells (APC), like macrophages and dendritic cells 
(DC), express TLR on their surface, bind these PAMP and initiate a signaling 
pathway that stimulates the host defenses through the induction of reactive 
oxygen and nitrogen intermediates (ROI and RNI). TLR, bound with these 
PAMP, initiates adaptive immunity as it activates APC by inducing production 
of pro-inflammatory cytokines and up-regulating co-stimulatory molecules.
FAftirar




Fig. 1.6 Activation of adaptive immunity through TLR 32
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TLRs are crucial not only in the early phase of infection when innate 
immunity is important, but also link innate and adaptive immunity throughout 
the entire process of the host defense response.
1.3.3. Interaction of PAMP with TLRs
LPS, the exogenous and the best-characterized PAMP as well as the 
major component of the outer membrane of Gram-negative bacteria, have 
been found to induce a variety of immunostimulatory responses including the 
production of pro-inflammatory cytokines such as IL-12 and inflammatory 
effector substances.
CD14, a glycosylphosphatidylinositol (GPI)-anchored protein expressed 
by mononuclear phagocytes, has been identified to bind to LPS but lacks an 
intracytoplasmic region, suggesting that it is unable to transduce a signal and 
hence TLR4, an additional membrane protein, has emerged as an important 
factor to transmit an LPS signal.^^ In addition to exogenous PAMP, TLR4 also 
has been revealed to bind to endogenous molecules such as heat shock 
protein (HSP) to induce an inflammatory response in normal mice.̂ ®
Gram-positive bacteria can also provoke immune responses similar to 
those generated by LPS. Based on its ability to form at least two distinct types 
of functional heterodimers with other TLR (TLR6 and TLR1), TLR2 can bind a 
variety of ligands including various glycolipids and peptidoglycan (PGN). '̂*
1.3.4. Immune Stimulating Activities of Alginate Mediated by TLR 2/4
Defined uronic acid polymers have been reported to induce cytokine 
production from human monocytes and poly-M is widely considered as the 
most potent tumor necrosis factor (TNF) inducer in uronic acid tribe.’®'
It has been found that poly-M from alginates has immunomodulating 
properties. Accompanying the important roles of TLRs in signal transduction, 
poly-M isolated from mucoid strains produced by P.aeruginosa can share with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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lipopolysaccharide the ability to stimulate cytokine production from human 
monocytes in a CD14-dependent co-receptor manner.®®
Membrane CD14 together with either TLR2 or TLR4/MD-2 could mediate 
an immune response by poly-M. Meanwhile, the ability of cytokine production 
induced by monocytes has been found to increase depending upon the 
composition of poly-M residues.®® Poly-G blocks have been reported not to be 
able to provoke cytokine production by monocytes and further reduce the level 
of cytokine production induced by poly-M blocks.®^
Moreover, blocking antibodies to TLR2 and TLR4 have been found to 
partly inhibit the tumor necrosis factor production induced by poly-M in human 
monocytes, and further inhibition was obtained in combination with 
antibodies.®® Alginate oligomers with molecular weights less than 2000 are 
also recognized by innate immune system through TLRs.®®
Unfortunately, the underlying mechanism of these bioactivities is still not 
clear and further study of structure-activity relationship of alginate oligomers is 
required to provide insight into the TLR-mediated recognition mechanism.
1.4. Objective of Thesis Project
TLRs play essential roles in mammalian immunity. Recently, it was 
reported that alginate oligomers have immunomodulating properties by 
binding to TLR2/4. In addition, previous research has elicited that optimal 
cytokine stimulatory activity from uronic acid polymers requires a certain 
polymer length and mainly p-1,4 diequatorial glycosidic linkages. In various 
degrees of un saturated oligomers mannuronate (M3-M9) and guluronate 
(G3-G9), G8 and M7 showed the most potential TNF-a-inducing activity 
even though G3 and M3, the smallest oligomers among PM and PG, also 
showed relatively high cytokine inducing activities compared with other 
larger oligomers.®®
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Insight in the mechanism of TLR-mediated recognition and signal 
transduction, leading to cytokine production, needs well-defined fragments 
of alginates and their functionalized derivatives. The chemical synthesis of 
alginate oligosaccharides has not been well studied. During the course of 
our investigation, the group of Van den Bos reported the successful 
synthesis of an alginate trisaccharide in which a-thio-monomannuronic acid 
derivatives were selected as glycosylation donors. Different donors 
(a-thio-monomannosides) have been chosen in our synthesis of p-1,4-di- 
and tri-D-mannuronic acid glycolipids. In the following chapters, the 
details of chemical synthesis of 1 / 2 are described.
The main objective of the thesis is to synthesize 
o//go-p-1,4-D-mannuronic acid glycolipids (1 & 2) (Fig. 1.7) as potential TLR 
ligands which may show immune stimulatory properties.
Fig. 1.7 Structure of p-1,4-D-mannuronic acid glycolipid 1 /2
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2. Synthesis of g-1,4-D-mannuronic Acid Glycolipids
2.1. General Features of Glycosylation Reactions'*'*
In glycosylation reaction, there are a number of important aspects that 
need to be considered. The following features will be taken into account in 
our synthetic strategy:
1. Monosaccharides have to be properly protected, by using protective 
groups, prior to the application of synthetic strategies aimed at 
oligosaccharide synthesis. The protection steps are generaly 
unavoidable and are a consequence of the polyhydroxylated nature 
of sugars.
2. Although hydroxyl groups on pyranose rings have different 
nucleophilicities that permit selective glycosylation to be 
accomplished with the sugar having several unprotected hydroxyls, 
this is not the general case in our glycosylation strategy.
3. Most commonly, for the glycosyl acceptor, it is necessary to follow a 
strategy in which all the hydroxyl groups are protected with the 
exception of the one to be glycosylated. For the glycosyl donor, 
besides the protection steps, it is essential to have a suitable 
activating group at the anomeric center, which in turn functions as a 
leaving group generating an oxocarhenium ion that is susceptible to 
nucleophilic attack by the acceptor.
4. For the formation of a 1,2-trans glycoside, it is common practice to 
take advantage of the protecting group at C-2.
5. Nucleophilic attack on the oxoca rhenium ion (Fig. 2.1) leads to the 
formation of a or p glycosidic linkages and highlights the numerous 
variables such as temperature, solvent, polarity, catalyst and 
protecting groups, that should be taken into account when a 
stereoselective product is desired.
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(PO)n'
( P O ) n ' l ^ — OR
^ . r ^ N u  ....
4  (ROM)
Nu ^ ____
P: Protective Group (PO jn '
L: Leaving group oxocarbnium cation
Fig. 2.1 Nucleophilic attacking on the oxocarbenium ion
6. Non participating groups and relatively non-polar solvents favor 
1,2-c/s-glycosylation products. A non-participating benzyl group has 
been chosen in the organic synthesis of target molecules.
2.2. Structural and Synthetic Features of Target Molecules
Compound 1 / 2  (p-1,4-D-mannuronic acid glycolipid) have been 
designed as glycolipids mainly considering the following aspects:
1. Naked small carbohydrates molecule would be rapidly cleared away 
from the biological sys tem,wh i l e  conjugation with lipids may 
stablize them and hence make them better drug agents than naked 
carbohydrates.
2. The concept of liposome formulation, a drug delivery platform to 
reduce toxicity and side effects as well as to slow down release 
speed, has been a concern and, therefore, two Cie-chains were 
introduced into molecule design in this thesis, since the 14- to 
18-carbon lipid chains is considered to be more efficient in liposome 
formulation.^
Our approach to target molecules, p-1,4-D-mannuronic acid glycolipid 1 
/ 2 (Fig. 2.2), mainly focuses on the 1,4-linked 1,2-c/s mannosyl relationship 
which is hard to achieve by normal stereocontrolled manner. Some
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methods exist for the challenging p-D-mannoside linkage, but they are not 
efficient until the remarkable methodology developed by Crich’s group 
recently. A similar method for the direct synthesis of p-D-mannosides has 
been utilized in our synthetic strategy involving in the diastereoselective 
P-glycosylation of 4,6-0-benzylidene protected a-thiomannoside donor with 
prepared acceptors ROM. A subsequent specific TEMPO / BAIB oxidation 
leads to target molecules 1 / 2 (Fig. 2.2).





X = S-Ph or S-Ph
Fig. 2.2 Crich's methodology followed by an oxidation step leads to 1/2
Several conformational characteristics feature p-glycosylation of 
D-mannosides in Crich’s methodology, including:
1. The presence of the 4,6-0-benzylidene acetal protective group at
1-thio functionalized mannoside donor 9 has a profound influence on 
the stereoselectivity of mannosylation reactions conducted by 
BSP/TfzO/DTBMP activated thioglycoside coupling protocol. The 
trans fused configuration of 4,6-0-benzylidene acetal protective 
group restricts the molecules from ring flexibility and hence make it 
increasingly difficult to reach a half-chair transition state from a chair 
ground state. The stereodirecting influence of 4,6-0-benzylidene 
protecting group arises from so called “torsionally disarming” effect 
on glycosyl cations (oxacarbenium ions), which effectively shifts all 
equilibria towards the covalent axial-a-mannosyl triflates and in turn 
promotes SN2-like displacements with the incoming acceptor ROM to
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41reach p-glycosylation.'
2. The smaller and non-participating 2-0-benzyl ether protective group 
stimulates the greater p:a ratios for secondary mannosyl acceptors 
ROM, compared with the other bigger steric bulk of the 0-2 
protecting groups such as 2-0-TBDMS (fe/t-butyldimethylsilyl) and
2-0-TMS (trimethylsilyl).'*^
2.3. Synthesis of p-1,4-di-D-mannuronic Acid Glycolipid 1














Fig. 2.3 Retrosynthetic analysis of glycolipid 1
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The strategy employed to produce the p-1,4-di-D-mannuronic acid 
moiety is to first synthesize the p-1,4-di-D-mannobiose unit, followed by an 
oxidation step to convert the mannose residues to the glycolipid 1 (Fig. 2.3). 
The 4,6-di-O-benzylidene protected methodology recently developed by 
Crich and co-workers offers an efficient method for the direct synthesis of 
p-D-mannosides. A similar strategy has been used to construct the 
p-1,4-di-D-mannobiose moiety.
2.3.2. Synthesis o f Lipid Anchor 6
Lipidated and benzylated pentaerythritol derivative 6 was prepared as 
the lipid anchor acceptor according to Scheme 1.
I  n-CigHsaBr, DMF,NaH, 50°C, 59%
  O   OvN/VN.AA/'v/N/
Neopentyl glycol, CSA, 
y CH2CI2 , 35°C, 95%
HO \
HO—  — O v ^ \^ / \ /v v s A /  ^
i. Benzene, Bu2SnO, reflux
ii. BnBr, Bu^N^Br, 70%
BnO— \
HO— ^ —
Scheme 1 Synthesis of lipidated anchor 6
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The start point of the synthesis was a known compound 3.'*® Two 
Ci6-lipid chains were introduced to 3 through 0-alkylation with 1-bromo 
-hexadecane and sodium hydride (deprotonating agent) in DMF for 48 
hours to offer monoketal-ether 4 in 59% yield. In this reaction, DMF acts as 
polar aprotic solvent since protic solvents and apolar solvents tend to slow 
the reaction rate strongly in an Sn2 attack.
Trans-ketalization of 4 with neopentyl glycol in the presence of 
camphorsulfonic acid (CSA) in anhydrous dichloromethane (DOM) 
furnished 0-alkyl diol 5 in 95% yield. Recrystallization was used here to 
purify 5 by using dichloromethane (DOM) as a suitable solvent.
Two other acidic hydrolysis reaction systems a (EtOAc / MeOH / HgO = 
10:1 : 0.2 and p-TsOH 0.1 eq. at r.t.) and b (EtOAc / Hexane / ethanediol = 
4 : 2 : 1  and p-TsOH 0.1 eq. at r.t.) also have been employed but gave lower 
yields (5% and 61 % respectively). The lower yields probably result from the 
low solubility of 4 in which two saturated Ci6-n-alkyl chains were connected 
and the relatively difficult intermolecular reaction. Actually, the 
mono-hydroxyl intermediate product has been competitively obtained under 
the conditions of the b system.
Monobenzylation of 5 by reflux with dibutyltin oxide (BugSnO), a 
deprotonating agent, in benzene at 90 °C for 16 hours and azeotropic 
removal of produced water, followed by addition of benzyl bromide and 
tetrabutylammonium bromide (Bu^N^^Br ) at the same temperature, provided 
compound 6 in 70% yield. A proposed mechanism (Fig. 2.4) of the 
monoderivatization of symmetric diol 5 using one of stannoxanes, dibutyltin 
oxide (BuaSnO), is shown. 1,2-Diol 5 is treated with BuaSnO with azeotropic 
removal of produced HgO to afford the requisite tin acetal (I). The 
stannylidene then goes through selective monobenzylation [(II), ( III)  and 
(IV)] with BnBr in the presence of nucleophlic catalyst Bu4N"^Br' to activate 
electrophilic substitution of the benzyl group of BnBr and finally provides 
desired compound 6.
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H O -a  /—
BugSnO
stannylidene (tin acetal)
BU4N Br'x^^ - 0 - ^ y —
Bii—.
( II)




with benzene at 90°C
Bn-Br
BnO \  /  ( \ / \ / \ / \ / \ / \ / \ / \ /
(III)









Fig. 2.4 Proposed monobenzylation mechanism of 5
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i. Pyridine, Acetic anhydride(Ac20), 0°c, 100 %. jv. PhCH(0Me)2. p-TsOH, Dry DMF, rt, 51 %.
ii. ̂ S H ,  BF3«(EtO)2 , DCM(anhydrous), r.t, 95 % v. NaH, DMF, Bn-Br, r.t, 95 %
iii. MeONa, MeOH(anhydrous), PH=10, r.t, 100 %.
Scheme 2 Synthesis of mono-a-thiomannoside donor 9
The synthesis of thiomannoside donor 9 reported by Crich and 
co-workers 4? has been repeated (Scheme 2).
2.3.4. Synthesis of Monosaccharide 10
Crich and co-workers recently developed an efficient method for the 
direct synthesis of p-D-mannosides. A similar protocol has been
employed here to produce mono-p-D-mannoside lipid 10 (Scheme 3).







P h ^ O  \
+
9 SPh
BSP, DTBMP, TfgO, 




Scheme 3 p-glycosylation of 9 with lipid anchor 6
Therefore, by activating 4,6-0-benzylidene protected thiomannoside 
donor 9 with 1-benzenesulfinyl piperidine (BSP) and 
trifluoromethanesulfonic anhydride (TfaO) in the presence of
2,6-di-ferf-butyl-4-methylpyridine (DTBMP) at -60 °C, the protocol offers 
1-a-mannosyl triflate intermediate. After the addition of two Ci6-chains 
attached lipid anchor acceptor 6 at -78°C, the protocol finally provides the 
desired p-mannoside 10 in 85% yield.
An appreciable rationale (Fig. 2.5) shows that BSP is first converted 
to corresponding sulfonium (I) and then sulfonium triflate (II) respectively, 
with TfzO in the presence of a non-nucleophilic hindered base DTBMP as 
neutralizer. (II) rapidly expels a sulfinate ester (III) to offer oxacarbenium 
cation (IV) which is trapped in turn by the triflate anion to give glycosyl 
triflate (V), and a following SN2-like attack of (V) with acceptor 6 produces 
p-D-mannoside lipid 10.























- 78 °C -  0 °C, 85%
10
OBn
Fig. 2.5 Mechanism of p-glycosylation of 
thiomannoside donor 9 with acceptor 6
The p-linkage has been confirmed by the value of c, h coupling 
constant of the anomeric carbon in 10 (̂ J c, h = 155.0 Hz ) and the value of 
the unusual, somewhat upfield, H-5 chemical shiftof Ô 3.28 (ddd, 1H, J 10.0, 
10.0, 4.5Hz,) in 10 with the 4,6-di-O-benzylidene protective group. The 
a-isomer is also formed in around 10% yield, but an analytically pure 
material has not been obtained.
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Neopentyl glycol, CSA, 
Anhydrous DCM, 35 °C, 90%
BzCI, pyridine, DMAP, 
DCM, -25 °C, 70%
11
12
Scheme 4 Deacetylation and regiobenzoylation of 10
Removal of the ketal on 10 with neopentyl glycol in the presence of 
camphorsulfonic acid (CSA) in anhydrous dichloromethane (DCM) liberates
4,6-diol 11 in 90% yield.
Compound 11 is selectively converted to 6-0-benzoate 12 in 70% yield 
(Scheme 4), through regioselective benzoylation with benzoyl chloride in 
anhydrous pyridine in the presence of 4-N,N-dimethylaminopyridine (a 
nucleophilic catalyst).
2.3.6. Synthesis of Disaccharide 13
Activation of the prepared 4,6-0-benzylidene protected thiomannoside 
donor 9 with 1-benzenesulfinyl piperidine and trifluoromethanesulfonic 
anhydride (BSP/TfaO) at -60°C, followed by the dropwise addition of
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mono-p-D-mannoside acceptor 12 at -78 °C in the presence of hindered 
base 2,6-di-ferf-butyl-4-methylpyridine (DTBMP) as neutralizing agent in 
anhydrous DCM provides the desired p-1,4-di-D-mannoside 13 in 67% yield 
(Scheme 5). The formed p-linkage in 13 is confirmed by the specific H-5 
signal f h  NMR (500 Hz, CDCI3): d 3.03 - 3.07 (ddd, J = 10.0, 10.0, 4.5 Hz, 
1H, H-5b)]. It is also confirmed by the ^Jc,h coupling constant of two 
anomeric carbons and the OH carbon of the benzylidene group [^^0 NMR 
(125 Hz, CDCI3): d 102.2 (^Jc,h= 155.5 Hz), 101.9 (^Jc,h =154.5 Hz), 101.3 
(̂ Jc,H = 157.9 Hz)]. A minor product, probably the a-isomer of 13 is also 
detected, but an analytically pure sample has not been obtained.
12
OBn












Scheme 5 p-Glycosylation to 13
2.3.7. Removal o f 4,6-di-O-benzylidene and Déacylation of 13
Using the same procedure as described earlier, removal of the
4,6-0-benzylidene protecting group of 13 is achieved through a trans-ketal 
reaction with neopentyl glycol in the presence of CSA in anhydrous DCM at 
35 °C to offer diol 14 in 90% yield. Déacylation of 14 with a catalytic amount
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of sodium methoxide (NaOMe) in dichloromethane -methanol (1:1 v/v) 
















Scheme 6 Deketalization and déacylation of 13
2.3.8. Regioselective Oxidation of Disaccharide 15
Regioselective oxidation of the primary hydroxyl group (C-6) in 15 to 
the carboxylic acid is furnished by the combination of 2,2,6,6-tetramethyl 
-piperridinyloxy free radical (TEMPO) and acidic oxidant 
[bis(acetoxy)iodo]benzene (BAIB) in DCM-H2O (2:1 v/v), where triol 15 is 
converted into its corresponding dicarboxylic acid 16 (Scheme 7) in 95% 
yield.





























hydrated aldehyde intermediate 
TEMPO/BAIB cycle
R-COOH 16
Fig. 2.6 Proposed oxidation mechanism of triol 15 with BAIB/TEMPO
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A proposed reaction pathway (Fig. 2.6) for the oxidation of triol 15 
has been illustrated here; after a ligand exchange around the iodine atom of 
BAIB, the developed acetic acid catalyzes the dismutation of the TEMPO 
radical to nitrosonium salt which quickly and selectively oxidizes two 
primary C- 6  hydroxyl groups in triol 15 to the corresponding aldehyde. The 
nitrosonium salt itself is converted to hydroxylamine which goes through a 
TEMPO/BAIB catalytic cycle to regenerate TEMPO radical in the presence 
of BAIB. The produced aldehyde is converted to hydrated aldehyde 
intermediate in the presence of H2O followed by another TEMPO/BAIB 
catalytic cycle to achieve desired dicarboxylic acid 16.
Considering that it is hard to obtain analytically pure dicarboxylic acid 
16 through silica gel chromatography because the carboxyl groups cause 
strong “drag tail”, dicarboxylic acid 16 was converted to its benzyl ester 17. 
Thus 16 was treated with benzyl bromide (BnBr) in the presence of 
potassium fluoride (KF as base) in DMF at room temperature to achieve 
benzyl ester 17 (Scheme 7) in 67% yield. The dicarboxylic acid 16 first 
reacts with basic potassium fluoride to produce the potassium carboxylate 
intermediate, a corresponding salt of 16, which in turn goes through a Sn2  
displacement toward BnBr. The polar aprotic solvent DMF was used to 
increase Sn2 attack, providing desired benzyl ester 17.
2.3.9. Global Débenzylation to Target Molecule 1
Hydrogenolysis of 17 to remove the benzyl protecting group was 
carried out in tetrahydrofuran (THF) -  water (4:1) under a hydrogen 
atmosphere in the presence of palladium on charcoal to furnish the target 
product p-1,4-di-D-mannuronic acid glycolipid 1 in 90% yield (Scheme 8 ). 
The structure of 1 has been confirmed by mass spectroscopy data 
{(MALDI-MS) calcd for C49H92O16 936.63[M]\ found 959.63 [M+Na]",
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981.62 [M-H+2Na]‘'}. A well resolved NMR spectrum was not obtained due 




Hz, Pd/C, THF / H2O (4:1), 90%
OH
Scheme 8  Hydrogenolytic débenzylation of 17 to target 1
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2.4. Synthesis of p-1,4-trl-D-mannuronic acid glycolipid 2
2,4.1. Synthetic Strategy of p-1,4-di-D-mannuronic Acid Glycolipid 2
A similar synthetic strategy (Fig. 2.7) as synthesis of 

















Fig. 2.7 Retrosynthetic analysis of p-1,4-fr/-D-mannuronic acid glycolipid 2 
2.4.2. Regioselective Protection of Diol 14
Regioselective benzoylation of diol 14 with benzoyl chloride (BzCI) in 
anhydrous pyridine in the presence of 4-N,N-dimethylpyridine (as a 
nucleophilic catalyst) at -25°C under Na atmosphere for 5 hours provides 18 
in 94% yield (Scheme 9). This yield has been observed to be higher than 
that of benzoylation of monosaccharide 11 (70%) (Scheme 4) to a great 
extent but the reason is unclear.




BzCI, DMAP, Pyridine-CH 2 Cl2  
-25°C to 0°C, 94%
18
Scheme 9 Regioselective benzoylation of diol 14
2.4.3. p-glycosylation o f Thiomannoside Donor 9 with Acceptor 18
p-glycosylation of 4,6-0-benzylidene protected thiomannoside donor 9 
with acceptor 18 has been employed to produce 19 (Scheme 10):
OBz
SPh OBn
BSP, DTBMP,TfgO, -60 "C, 





Scheme 10 p-Glycosylation of 9 with acceptor 18
Activation of the a-thiomannoside donor 9 with 1-benzene sulfinyl 
piperidine and trifluoromethanesulfonic anhydride (BSP/TfgO) at -60°C, 
followed by the dropwise addition of mono-p-D-mannoside acceptor 18 at 
-78°C in the presence of the hindered base 2,6-di-tert-butyl-4-
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methylpyridine (DTBMP) in anhydrous DCM provides the desired 
P-1,4-tri-D-mannoside 19 in 51% yield (the yield was modified to 61% after 
partial starting material was recovered), p-linkage in 19 is confirmed by the 
specific H-5 signal f h  NMR (500 MHz, CDGI3): Ô 2.97 (ddd, 1H, J4c,5c/5c,6c 
9.5Hz, Js.ec 5Hz, H-5c)] and the Ĵc,h coupling constant of three anomeric 
carbons and the OH carbon of the benzylidene group [^^0 NMR (125 
Hz,CDCI3): d 102.5 (^Jc,h = 156.5 Hz), 102.1('Jc,h =152.3H z), 101.6  ('Jc,h = 
151.6 Hz), 101.5 (^Jc.H= 153.1 Hz)].
2.4.4. Preparation of Tetraol 21
Preparation of tetraol 21 is the same as that of triol 15: removal of
4,6-di-O-benzylidene of 19 was carried out through a trans-ketal reaction 
with neopentyl glycol in the presence of camphorsulfonic acid (CSA) in 
anhydrous dichloromethane (DCM) at 35°C to liberate 4,6-diol 20. 
Déacylation of 20 with sodium methoxide (NaOMe) in 
dichloromethane-methanol (DCM : MeOH = 1:1 v/v) under pH=9 - 10 at 















Scheme 11 Deketalization and déacylation of 19
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BAIB, TEMPO, CH 2 CI2 -H2 O (2:1), rt, 64%
22
OBn




Scheme 12: Regioselective oxidation and benzylation of 21
Regioselective oxidation of the primary hydroxyl (C-6) in 21 to its 
carboxylic acid is achieved by the combination of TEMPO free radical and 
BAIB in the presence of DCM-H20(2:1), where triol 21 is converted into its 
corresponding tricarboxylic acid 22 in 64% yield. The same consideration 
as described for 16, benzyl estérification of 22 with benzyl bromide (BnBr) 
in the presence of potassium fluoride (KF) in DMF at room temperature, 
yields benzyl ester 23 in 64% yield (Scheme 12). p-linkage is confirmed by 
the specific c, h coupling constant of the anomeric carbons in 23 [(^^C 
NMR (125.664 Hz,CDCl3): d 102.3 (^J c, h  = 157.7 Hz), 102.5 ( ' j  c, h  
=155.6Hz), 103.2 ( ' j  c , h  = 155.3 Hz)].
2.4.6. Global Débenzylation to Target Molecule 2
Hydrogenolysis of 23 has been carried out in tetrahydrofuran (THF) -  
H2O (4:1 v/v) under hydrogen atmosphere in the presence of palladium on
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charcoal to achieve the target product p-1,4-fr/-D-mannuronic acid 
glycolipid 2 in 90% yield (Scheme 13). The structure of 2 has been 
confirmed by mass spectroscopy data {MALDl-MS) calcd for C55H100O22 















Scheme 13 Removal of benzyl protecting groups of 23
2.5. Concluding Remarks
p-D-mannuronic acid oligomers have a 1,2-c/s mannosyl relationship 
which makes it hard to obtain p-glycosylation in a commonly 
stereocontrolled manner. Van Den Bos and co-workers have recently 
presented a facile synthetic route^® toward p-linked mannuronic acids, in 
which a carboxylic ester function on C-5 of the mannuronate donors have 
been used to sufficiently influence the electronic surrounding around the 
anomeric center and allow good to excellent p-selectivities.
In this thesis, Crich’s methodology has been used to introduce 
p-1,4-D-mannoside linkage by application of diastereoselective 
p-glycosylation of 4,6-0-benzylidene protected thiomannoside donor 
bearing nonparticipating benzyl group at 0-2 and 0-3 positions with 
suitable acceptors, followed by a 2,2,6,6-tetramethylpiperidinyloxy free
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radical (TEMPO) / [bis(acetoxyiodo] benzene (BAIB) regioselective 
oxidation step to achieve targets: p-1,4-cf/ & fr/-D-mannuronic acid oligomer 
moieties (1 & 2).
An efficient route for the synthesis of p-1,4-D-mannuronic acid 
glycolipids 1 and 2 designed as potential ligands for TLR2/4 has been 
described. The strategy presented here shall be applicable to the synthesis 
of larger o//go-p-1,4-D-mannuronic acids.
The initial biological evaluation of compounds 1 and 2 with respect to 
the immune stimulating and modulating properties is underway.




TLC was performed on Silica Gel 6 O A - F 2 5 4  (Silicycle) with detection by 
quenching of fluorescence (254 nm), by dipping into 15% solution of H2SO4 
and/or mostaine [ammonium molybdate (NH4)6Mo7 0 2 4 -4 H2 0  ( 2 0  mg) and 
Cerium (IV) sulfate Ce(S0 4 ) 2  • XH2O in 10 % sulfuric acid (400 ml)] 
followed by charring at -120 °C.
Column chromatography was performed on Silica Gel 60 (Silicycle, 
40-63 pm).
Optical rotations were measured with a Perkin-Elmer 241 polarimeter 
at 22+2°C.
NMR spectra were recorded at 499.9 MHz (Varian Unity Inova 500 
MHz) in solutions of CDCI3 [internal Me4Si (TMS), 6  0 ppm). Coupling 
constants can be ascribed a resolution of ± 0.5 Hz. ^̂ C NMR spectra were 
recorded at 125 MHz on the same instruments in CDCI3 (Ô 77.26 ppm).
Matrix-assisted laser desorption / ionization (MALDI) mass spectra 
(MALDI-MS) were obtained from a Biflex-IV MALDI linear / reflector 
instrument at the University of Manitoba.
Elemental analyses were carried out on a CEC (SCP) 240-XA Analyzer 
instrument by Lakehead University Instrumentation Laboratory (LUIL).
All commercial reagents were used as supplied. Solvents for 
anhydrous reactions were dried according to literature procedures. Toluene 
was distilled over sodium; pyridine and dichloromethane were distilled over 
calcium hydride; methanol was distilled from magnesium turnings and a 
catalytic amount of iodine.
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3.2. Synthetic Procedures and Structure Characteristics
1.5-dloxaspiro[5,5]undecande-3,3-dimethanol (3).
3 was prepared according to the literature procedure.®^
RfO.36 (CHzClz/MeOH, 9 : 1).
1.5-dioxaspiro[5,5]undecande-3,3-dihexadecyloxymethyl ether (4).
CXDCZZZ
To a completely dissolved solution of 1-bromo hexadecane (26.2 mL, 
85.44 mmol, 2 eq.) in anhydrous DMF (60 mL) was carefully added NaH 
(2.6 g, 102.65 mmol, 2.4 eq.) and heated to 50 °C in an oil-bath followed by 
dropwise addition of 3 (9.25 g, 42.77 mmol, 1.0 eq.) which was 
predissolved in 20 mL anhydrous DMF. The mixture was then left overnight 
before being washed with ice-water (100 mL), taken up in EtOAc (3x120 
mL), dried over Na2S0 4 , filtered and concentrated. The residue was further 
purified by chromatography on silica gel (eluent: hexane / ethyl acetate = 
30 : 1 / 20 : 1 v/v) and concentrated to provide 4 (14.31g, 59%) as a white 
powder.
Rf0.41 (Hexane / EtOAc, 20 : 1 v/v).
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6 H, J 3.5 Hz, 2 CH3), 1.26 (bs, 
52 H, 2 C13H26), 1.40 (bs, 2 H, 1 CH2), 1.52 (bs, 8 H, 4 CH2), 1.75 (bs, 4 H, 2 
CH2), 3.38 (t, 8H, J 7.0 Hz, 4 CH2O), 3.74 (s, 4H, 2 CH2O).
NMR (125 MHz, CDCI3): 5 14.40, 22.83, 22.96, 25.98, 26.43, 29.64, 
29.77, 29.82, 29.91, 29.93, 29.98, 32.19, 32.87, 39.23, 62.30, 70.61, 71.88, 
98.21
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To a solution of 4 (14.31 g, 21.52 mmol, 1.0 eq.) and neopentyl glycol 
(9 g, 86.1 mmol, 4.0 eq.) in anhydrous DCM (200 mL) at 35 °C, conducted 
under N2 atmosphere, was added CSA (camphorsulfonic acid) (1.0 g, 4.3 
mmol, 0.2 eq.) with vigorous stirring. The mixture was left overnight and 
quenched with saturated aqueous NaHCOs, washed with ice-water (200 
mL), taken up in DCM (3 x 200 mL), dried over Na2S0 4  and followed by 
recrystallization in which the solution (800 mL) was first rotary evaporated 
under reduced pressure to 200 mL of solution, and then cooled to -30 °C to 
get a suspended white crystal which was quickly filtered and washed with 
cooled DCM (-30 °C). The same procedure was operated 3 times. The 
collected crystals were rotary evaporated under reduced pressure to 
provide compound 5 (12.1 g, 95%) as a white powder.
RfO.45 (Hexane / EtOAc, 2 : 1 v/v).
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6 H, J 3.5 Hz, 2 CH3), 1.26 (bs, 
52 H, 2 C13H26). 1.57 (bs, 4 H, 2 CH2), 2.80 (t, 2 H, J 6.5 Hz, 2 OH), 3.42 (t, 
4 H, J 6.5 Hz, 2 OCH2). 3.51 (s, 4 H, 2 CH2O), 3.64 (bs, 4 H, 2 CH2 OH ).
'®C NMR (125 MHz, CDCI3): 5 14.14, 22.71, 29.38, 29.45, 29.52, 29.61, 
29.64, 29.68, 29.70, 29.72, 31.94, 31.98, 44.5, 65.48, 72.06, 73.23.
Anal. Calcd for C37H76O4: C, 75.97; H, 13.09. Found: C, 75.85; H, 
12.87.
2,2-dlhexadecyloxymethyl-1 -O-benzyl-3-propanol (6).




A solution of 5 (5.85 g, 10.0 mmol, 1.0 eq.) and dibutyltinoxide (2.49 g,
10.0 mmol, 1.0 eq.) In benzene (100 m l) was kept under reflux for 16 hours 
at 90 °C In an oll-bath with removal of produced water by a Dean-Stark trap, 
followed by addition of tetrabutylammonlan bromide (3.22 g, 10.0 mmol, 1.0 
eq.) and dropwlse addition of benzylbromlde (2.38 ml, 20.0 mmol, 2.0 eq.) 
which was pre-dlssolved in 5ml benzene. The mixture was kept under reflux 
until TLC Indicated a complete reaction and then quenched with saturated 
aqueous NaHCOs (20 m l). The residue was washed with ice-water (120 
m l), extracted with EtOAc (3 x 120 ml), dried over Na2S0 4 , filtered, 
concentrated, purified by column chromatography on silica gel (eluent: 
hexane / ethyl acetate = 20 : 1 / 12 : 1 v/v) and concentrated to provide 
compound 6 (4.72 g, 70%) as a white powder.
RfO.36 (Hexane/ EtOAc, 10:1 v/v).
NMR (500 MHz, CDCI3): 5 0.88 (t, 6 H, J 3.5 Hz, 2 CH3), 1.25 (bs, 
52 H, 2 C13H26), 1.52 (bs, 5 H, 1 OH and 2 CH2), 3.38 (t, 4 H, 2 OCH3), 3.47 
(s, 4 H, 2 CH2O), 3.52 (s, 2 H, CH2 OH), 3.73 (s, 2 H, CH2OH ), 4.50 (s, 2 H, 
2 PhCHH), 7.27 - 7.35 (m, 5 H, Arom).
NMR (125 MHz, CDCI3): 5 14.38, 22.95, 26.42, 29.62, 29.74, 29.83, 
29.89, 29.91, 29.93, 29.96, 32.19, 45.10, 66.84, 71.01, 71.88, 72.05, 73.71, 
126.60, 127.71, 128.54 (5 CH Arom), 138.76 (1 Cq Ph).




O '  "  
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To a solution of 9 (1.63 g, 3.0 mmol, 1.5 eq.) in anhydrous DCM (50 m l) 
conducted under N2 atmosphere were added 2 g of activated 4Â molecular 
sieves, 1-benzenesulflnyl piperidine (BSP) (0.69 g, 3.3 mmol, 1.65 eq.) and
2,6-di-fe/t-butyl-4-methylpyridine (DTBMP) (1.26 g, 6.12 mmol, 3.0 eq.). 
The mixture was kept stirring for 1 hour at r.t.. Trifluoromethanesulfonic 
anhydride (TfgO) (0.56 ml, 3.3 mmol, 1.65 eq.) was added dropwise at -60 
°C and 5 min later, a solution of 6 (1.35 g, 2.0 mmol, 1.0 eq.) which was 
pre-dissolved in 10 m l anhydrous DCM, was added dropwise at -78 °C. 
The mixture was kept vigorously stirring at -78 °C for 2 more hr and then 
warmed up to r.t. before being quenched with saturated aqueous NaHCOa 
(10 ml), washed with ice-water (80 ml), extracted with DCM (3 x 80 m l), 
dried over Na2S0 4 , filtered and concentrated. The residue was further 
purified by column chromatography on silica gel (eluent: hexane / ethyl 
acetate = 20 : 1 /10  :1 v/v) and concentrated to provide compound 10 (2.1 
g, 85%) as a syrup.
RfO.35 (Hexane / EtOAc, 8 : 1 v/v).
[a]D^"-15.7 (C 0.66, CHCI3).
^H NMR (500 MHz, CDCI3): ô 0.88 (t, 6 H, J 3.5 Hz, 2 CH3 ), 1.26 (bs, 
52 H, 2 C13H26), 1.51 (bs, 4 H, 2 CH2), 3.28 (ddd, 1 H, Js.ea = J 4,s 10.0, Js.eb
4.5 Hz, H-5), 3.32 - 3.38 (m, 4 H), 3.39 - 3.54 (m, 8 H), 3.83 (d, 1 H, J 2,3 3.0 
Hz, H-2), 3.92 (t, 1 H, Js.ea = Jea.eb 10.0 Hz, H-6a), 3.99 (d, 1 H, Ü3 ,4 10.0 Hz, 
H-3), 4.19 (dd, 1 H, Ja,4 = J^slO.O Hz, H-4), 4.30 (dd, 1 H, Jga.eb 10.0, Jg.eb
4.5 Hz, H-6b), 4.37 (s, 1 H, H-1), 4.41,4.50, 4.57, 4.68, 4.79, 4.95 (6d, 1 H
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
43
each, J 12.0 Hz, 6  PhCHH), 5.60 (s, 1 H, CHPh), 7.21-7.50 (m, 20 H, 4 
CeHs).
"C  NMR (125 MHz, CDCI3): 5 14.36 (2 CH3), 22.93 (2 CH2), 26.49 (2 
CH2), 29.61, 29.77, 29.87, 29.90, 29.92, 29.95 ( 2  C11H22), 32.18 ( 2  CH2), 
45.46 (1 Cq), 67.76, 68.83, 69.81, 69.88, 69.90, 70.65, 71.80, 71.81, 72.62, 
73.50, 74.81, 76.04, 78.28, 78.87, 101.55, 103.44 (C-1, CHPh, ^Jc,h 154.6, 
155.8 Hz), 126.26, 127.55, 127.57, 127.71, 127.72,128.35, 128.43, 128.49, 
128.75, 129.00 (20 CH Arom), 137.86, 138.61, 138.72,139.07 (4 Cq Ph). 





To a solution of 10 (2.10 g, 1.92 mmol, 1.0 eq.) and neopentyl glycol 
(0.8 g, 7.68 mmol, 4.0 eq.) in anhydrous DCM (20 m l) at 35 °C, conducted 
under N2 atmosphere, was added CSA (0.30 g, 1.15 mmol, 0.6 eq.) with 
vigorous stirring. The mixture was left overnight and TLC checked until a 
complete reaction followed by a work up: quenched with saturated aqueous 
NaHCOs, washed with ice-water, extracted with EtOAC, dried over NagSO#, 
filtered, concentrated, purified by column chromatography on silica gel 
(eluent: hexane / ethyl acetate = 5 : 1 / 2 : 1 v/v) and concentrated under 
vacuum to provide compound 11 (1.74 g, 90%) as a syrup.
RfO.36 (Hexane / EtOAc, 5 : 4 v/v).
[a]o^ -40.4 (C 0.37, CHCI3).
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6 H, J 3.5 Hz, 2 CH3), 1.25 (bs, 
52 H, 2 C13H26). 1.52 (bs, 4 H, 2 CHz), 3.25 (dd, 1 H, J34 9.5, J2.3 3.0 Hz,
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H-3), 3.27 - 3.30 (m, 1 H), 3.34 - 3.38(m, 4 H), 3.40, 3.41, 3.44, 3.46, 3.48 
(5 d, 5 H. J 9.0 Hz, CCHHO), 3.51 (s, 1 H, OH-C-6 ), 3.54 (d, 1 H, J 9.0 Hz, 
CCHHO), 3.80 (dd, 1 H, Jea.eb 12.0, Jg.e 6.0 Hz, H-6 a), 3.85 (d, 1 H, H-1), 
3.91 (t, 1 H, H-4), 3.92, 3.99 (2 d, 2 H, J 9.0 Hz, CCHHO), 4.24 (1 d, 1 H, J
13.0 Hz, 1 PhCHH), 4.39 (s, 1 H, OH-C-4), 4.44, 4.45, 4.52, 4.69, 4.91 (5 d, 
5 H, J 13.0 Hz, 5 PhCHH), 7.23 - 7.39 (m, 15 H, 3 CgHs).





To a solution of 11 (480.0 mg, 0.48 mmol, 1.0 eq.) and 
4-(dimethylamino) -pyridine (4-DMAP) (7.6 mg, 0.048 mmol, 0.1 eq.) in 5 
mL pyridine at -25 °C was added benzoylcholoride (0.061 ml, 0.53 mmol, 
1.1 eq.) which was pre-dissolved in 1 mL anhydrous DCM. The mixture was 
kept stirring for 2 hours at -25 °C and allowed to warm up to r.t. before a 
TLC check indicated a complete reaction. The mixture was then diluted in 
100 mL EtOAc followed by washing with 30 ml 4 M HCL before being 
quenched with saturated aqueous NaHCOa, washed with ice-water (150 
mLI), extracted with EtOAC (3x150 ml), dried over Na2S0 4 , filtered, 
concentrated, purified by column chromatography on silica gel (eluent: 
hexane / ethyl acetate = 1 0 : 1 / 4 : 1  v/v) and concentrated under vacuum 
to provide compound 12 (370 mg, 70%) as a syrup.
RfO.63 (Hexane / EtOAc, 2 : 1 v/v).
[a]o^  ̂-35.0 (C 0.38, CHCI3).
’ H NMR (500 MHz, CDCI3): 5 0.88 (t, 6  H, J 3.5 Hz, 2 CH3), 1.26 (bs, 
52 H, 2 C13H26). 1.49 (bs, 4 H, 2 CH2), 2.90 (bs, 1H, 1 OH), 3.29 -  3.35 (m.
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4 H), 3.40 - 3.55 (m, 6  H), 3.85 (d. 1 H, J i ,2 3.0 Hz, H-2), 4.02, 4.04 (2 d, 2 H, 
J 9.5 Hz), 4.35 (d, 1 H, J 12.0 Hz, 1 PhCHH), 4.39 (s, 1 H, H-1), 4.41, 4.48 
(2 d, 2 H, J 12.0 Hz, 2 PhCHH), 4.57 (ddd, 1 H, J3,4/4,5 12.0, J 6.0 Hz, H-4),
4.67, 4.69, 4.93 (3 d, 3 H, J 12.0, 3 PhCHH), 7.20 - 7.48 (m, 18 H, 4 CeH5),
8.05 (d, 2 H, J2.6 = J3,5 8.0 Hz, 2 Hortho in Bz).
" c  NMR (125 MHz, CDCI3): 5 14.30 (2 CH3), 22.85 (2 CH2), 26.38 (2 
CH2), 29.52, 29.68, 29.77, 29.82, 29.85, 29.87 ( 2  C11H22), 32.09 ( 2  CHg), 
45.35 (1 Cq), 64.35, 66.95, 69.77, 69.84, 69.86, 70.18, 71.35, 71.69, 71.71,
73.39, 73.53, 74.45, 81.56, 73.94, 102.86 (C-1 , Je, h  154.6 Hz), 126.99, 
127.40, 127.47, 127.85, 127.96, 128.19, 128.27, 128.32, 128.34, 128.58,
129.96 (20 CH Arom), 132.91 (1 Cq In PhCOQ), 137.89, 138.93, 138.99 (3 
Cq in PhCHz), 166.82 (PhCOO).






To a solution of 9 (245.0 mg, 0.41 mmol, 1.5 eq.) in anhydrous DCM 
(10 mL), conducted under N2 atmosphere, were added 4Â molecular sieves,
1-benzenesulfinyl piperidine (BSP) (102.7 mg, 0.45 mmol, 1.65 eq.) and
2,6-di-terf-butyl-4-methylpyridine (DTBMP) (186.6 mg, 0.83 mmol, 3.0 eq.). 
The mixture was kept stirring for 1 hour at r.t.. Trifluoromethanesulfonic 
anhydride (Tf2 0 ) (0.08 ml, 0.45 mmol, 1.65 eq.) was added dropwise at -60 
°C and 5 min later, a solution of 12 (330.0 mg, 0.27 mmol, 1.0 eq.), 
pre-dissolved in anhydrous DCM (5 ml), was added dropwise at -78 °C,. 
The mixture was kept vigorously stirring at -78 °C for 2 more hr and allowed 
to warm up to r.t. before being quenched with saturated aqueous NaHCOa,
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washed with ice-water(15 mL), extracted with DCM (3x15 mL), dried over 
N3 2 S0 4 , filtered, concentrated, purified by column chromatography on silica 
gel (eluent: hexane / ethyl acetate = 1 0 : 1 / 5 : 1  v/v) and concentrated 
under vacuum to provide compound 13 (291.0 mg, 67%) as a syrup.
RfO.64 (Hexane / EtOAc, 5 : 2 v/v).
[a]o^  ̂-26.8 (C 0.40, CHCI3).
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6  H, J 3.5 Hz, 2 CH3), 1.25 (bs, 
52H,2Ci3H26), 1.46 (bs, 4 H, 2 CH2), 3.05 (ddd, 1 H, J4,s = Js.eb 10.0, Js.eb’
4.5 Hz, H-5b), 3.28-3.32 (m, 4 H), 3.36-3.43 (m, 4 H), 3.45-3.52 (m, 4 H), 
3.49 (dd, 1 H, J4 ,5  10.5, J5 .6 4.5 Hz, H-5a), 3.54, 3.59 (2 dd, 2 H, Ja.a 3.0, 
Ja,4 9.5 Hz, H-3a & H-3b), 3.67 (dd, 1 H, J 10.0 Hz, H-6 b), 3.83, 3.93 (2 d, 2 
H, Ü2,3 3.0 Hz, H-2a & H-2b), 4.00 (d, 1 H, Jsb.eb-10.0 Hz, H-6 b’), 4.10, 4.16 
(2 t, 2 H, Ü3 ,4 = J 4 ,5  9.0 Hz, H-4a & H-4b), 4.38 (d, 1 H, J 12.5 Hz, PhCHH), 
4.42 (s, 1 H, H-1), 4.43 (d, 1 H, J 12.5 Hz, PhCHH),4.50 (2 d, 2 H, Jsa.ea 4.5 
Hz, 2H-6a), 4.55, 4.57 ( 2 d, 2 H, J 12.5 Hz, 2 PhCHH), 4.60 (s, 1 H, H-1), 
4.66, 4.67, 4.69, 4.88, 4.83, 4.89 ( 6  d, 6  H, J 12.5 Hz, 6  PhCHH), 5.51 (s, 1 
H, PhCH), 7.23-7.53 (m, 32 H, CH Arom), 7.52 (t, 1 H, Ja, 4  = J 4 ,5  7.5 Hz, 
H-4 in Bz), 8.03 (d, 2 H, J2 , 3 = J 5,e 8.0 Hz, H-2 & H- 6  in Bz).
"C  NMR (125 MHz, CDCI3): 5 14.40 (2 CH3), 22.95 (2 CH2), 26.45 (2 
CH2), 29.63, 29.79, 29.89, 29.92, 29.95, 29.97 ( 2  C11H22), 32.18 ( 2  CH2),
45.43 (1 Cq), 64.09, 67.63, 68.74, 69.86, 69.89, 70.23, 71.81, 71.83, 72.10,
72.56, 73.47, 73.54, 73.98, 74.78, 75.39, 76.16, 77.32, 77.47, 78.55, 78.67,
80.03, 101.57,102.14, 102.48 (C-1 a, C-lb, CHPh, Jc, h 157.5, 153.7, 155.4 
Hz),126.32, 127.40, 127.49, 127.52, 127.68, 127.72, 127.75, 128.02, 
128.31, 128.37, 128.43, 128.54, 128.55, 128.63, 129.05, 130.01, 130.17 
(35 CH Arom), 133.24 (1 Cq in PhCOO), 137.79, 138.54, 138.77, 138.82, 
139.10,139.12 (5 Cq in PhCHz &1 Cq in PhCH),166.55 (PhCOO).
Anal. Calcd for C98Hi3 4 0 is* H2O: C, 74.96; H, 8.72. Found: C, 74.98; H,
9.07.






To a solution of 13 (105 mg, 0.07 mmol, 1.0 eq.), neopentyl glycol (30 
mg, 0.28 mmol, 4.0 eq.) and anhydrous DCM (20 ml) at 35 °C, conducted 
under Ng atmosphere, was added CSA (10 mg, 0.042 mmol, 0.6 eq.) with 
vigorous stirring. The mixture was left overnight and TLC checked until a 
complete reaction followed by a work up: quenched with saturated aqueous 
NaHCOs, washed with ice-water (20 ml), extracted with EtOAC (3 x 20 mL), 
dried over Na2S0 4 , filtered, concentrated, purified by column 
chromatography on silica gel (eluent: hexane / ethyl acetate = 2 : 1 / 5 : 4 
v/v) and concentrated under vacuum to provide compound 11 (84.5 mg, 
82%) as a syrup.
RfO.38 (Hexane / EtOAc, 5 : 3 v/v).
[a]o^  ̂-39.0 (C 0.34, CHCI3).
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6  H, J 3.5 Hz, 2 CH3),1.25 (bs, 52 
H, 2 C13H26), 1.48 (bs, 4 H, 2 CH2), 3.07 (m,1 H, H-5b), 3.20 (dd, 1 H, J3 4 
9.5, J2 ,3  3.5 Hz, H-3), 3.30 - 3.34 (m, 4 H), 3.38 - 3.42 (m, 4 H), 3.44 - 3.56 
(m, 4 H), 3.63 (m, 1 H, H-5a), 3.65, 3.72 (2 dd, 2 H, Jeb.eb' 12.5, Js eb — J 5,6b'
3.5 Hz, H-6 b' & H-6 b), 3.86 (d, 1 H, Ü2 ,3  3.0 Hz, H-2), 3.88 (t, 1 H, J 9.5 Hz, 
H-4b’), 3.92 (d, 1 H, Ü2 ,3  3.0 Hz, H-2), 4.00 (d, 1 H, J 9.5 Hz), 4.05 (s, 1 H, 
H-lb), 4.23 (t, 1 H, J 9.5Hz, H-4b), 4.31, 4.40 (2 d, 2 H, J 12.5 Hz, 2 
PhCHH), 4.46 (dd, 1 H, Jsa.ea’ 12.0 Hz, H-6 a), 4.47, 4.48, 4.55 (3 d, 3 H, J
12.5 Hz, 3 PhCHH), 4.63 (dd, 1 H, Jea.ea' 12.0 Hz, H-6 a’), 4.68, 4.72, 4.76, 
4.83, 4.92 (5 d, 5 H, J 12.5 Hz, 5 PhCHH), 7.22 - 7.55 (m, 27 H, CH-Arom), 
7.54 (t, 1 H, J3,4 = J 4.5 7.5 Hz, H-4 in Bz), 8.04 - 8.06 (d, 2 H, J2,3 = J 5, e 8.5 
Hz, H-2 & H- 6  in Bz).
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'"C NMR (125 MHz, CDCI3): 5 14.36 (2 CH3), 22.93 (2 CHz), 26.43 (2 
CHz), 29.59, 29.75, 29.85, 29.88, 29.91, 29.93 ( 2  C11H22), 32.15 ( 2  CHz),
45.44 (1 Cq), 61.42, 62.65, 64.17, 67.07, 69.75, 69.80, 70.14, 71.37, 71.74, 
71.76, 72.35, 73.39, 73.58, 74.10, 74.44, 74.60, 75.18, 75.74, 75.94, 79.55, 
81.94, 101.41, 102.57 (C-la, C-lb, Jc.h 155.7, 157.2 Hz), 127.49, 127.52, 
127.58, 127.66, 127.76, 127.85, 128.00, 128.16, 128.29, 128.36, 128.41, 
128.42, 128.56, 128.71, 128.75, 129.98, 130.06 (30 CH Arom), 133.42 (1 
Cq in PhCOO), 137.80, 138.48, 138.74, 138.99, 139.11 (5 Cq in PhCHz), 
166.66 (PhCOO).





To a solution of 14 (370.0 mg) dissolved in MeOH : DCM=2:1 (30 mL) 
at r.t. was added MeONa dropwise until the pH of the solution reached 10. 
The mixture was kept stirring for 17 hr followed by TLC check indicating a 
complete reaction and then Resin-RCOOH was added until the pH=7, 
followed by filtration and concentration under vacuum to provide compound 
15 (319 mg, 92%) as a syrup.
Rf0.21 (Hexane / EtOAc, 1 : 1 v/v).
[a]o"^ -42.0 (C 0.29, CHCI3).
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6 H, J 3.5 Hz, 2 CH3), 1.25 (bs, 
52 H, 2 C13HZ6), 1.51 (bs, 4 H, 2 CHz), 2.24 (b, 3 H, 3 OH), 3.19 (m, 1 H,), 
3.29-3.51 (m, 13 H), 3.70 (d, 1 H, J 12.5 Hz), 3.73 (d, 1 H, J 13.5 Hz), 3.81, 
(s, 1 H), 3.84 (d, 1 H, J 12.0 Hz), 3.87 (dd, 1 H, J 10.0 Hz), 3.91 (s, 1 H),
3.96 (d, 1 H, J 9.5 Hz), 4.11,4.14 (2 t, 2 H, Ja, 4  = J 4,s 9.5 Hz, H-4a & H-4b),
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4.37 (s, 1 H, H-1a or H-1b), 4.38, 4.49, 4.43, 4.50, 4.56 (5 d, 5 H, J 12.5 Hz, 
5 PhCHH), 4.59 (s, 1 H, H-la or H-lb), 4.67, 4.73, 4.85,4.78, 4.88 (5 d, 5 H, 
J 12.5 Hz, 5 PhCHH), 7.24 - 7.34 (m, 25 H, 25 CH Arom).
'^C NMR (125 MHz, CDCI3): 5 14.37 (2 CH3), 22.93 (2 CHz), 26.47 (2 
CHz), 29.61, 29.77, 29.87, 29.90, 29.93, 29.95 ( 2  CnHzz), 32.16 ( 2  CHz),
45.55 (1 Cq), 62.09, 63.01, 67.56, 69.68, 69.72, 71.54, 71.89, 72.43, 73.02,
73.52, 74.20, 74.49, 74.52, 74.83, 75.37, 75.71, 75.76, 76.64, 80.29, 82.20, 
101.60, 102.56 (C-la, C-lb), 127.21, 127.43, 127.52, 127.61, 127.63, 
127.72, 127.73, 127.78, 127.80, 127.92, 128.19, 128.23, 128.36, 128.38,
128.46, 128.47, 128.54, 128.78 (25 CH Arom), 137.88, 138.68, 138.75 (2),
139.06 (5 Cq in PhCHz).





O O B n O O B n
O B n
To a flask charged with 15 (300.0 mg, 0.22 mmol, 1.0 eq ),
2,2,6,6-tetramethyl -piperridinyloxy free radical (TEMPO) (21.0 mg, 0.132 
mmol, 0.6 eq.) and [bis(acetoxy)iodo]benzene (BAIB) (425.0 mg, 1.32 
mmol, 6.0 eq.) at r.t., was added 4 mL DCM and 2 mL H z O  with vigorous 
stirring. The reaction mixture was stirred for 2 hr until a TLC check indicated 
complete conversion of the starting material to a lower running spot, 
followed by a work up: being quenched with aqueous NazSzOs (1 0 % in 
H z O ) .washed with ice-water (10 mL), extracted with DCM (3x10 mL), dried 
through NazS0 4 , filtered, concentrated, purified by column chromatography 
with silica gel (eluent: H / E / MeOH / HO Ac = 3 : 1 : 0.1 : 0.2 v/v) and
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concentrated under vacuum to afford pure compound 16 (291 mg, 95%) as 
a syrup.
Rf 0.32 (Hexane / EtOAc / MeOH / HO Ac, 3 : 1 : 0.1 : 0.2 v/v).
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6 H, J 3.5 Hz, 2 CH3), 1.25 (bs, 
52 H, 2 C13H26), 1.48 (bs, 4 H, 2 G H z ), 3.31 - 3.47 (2 m, 13 H), 3.58, 3.72 (2 
d, 2 H, J 9.5 Hz, H-5a & H-5b), 3.79 (d, 1 H, Jz, 3 3.0 Hz, H-2b), 3.91, 3.94 (2 
d, 2 H, J 9.0 Hz) , 3.97 (d, 1 H, Jz,3 3.0 Hz, H-2a), 4.19, 4.34 (2 t, 2 H, Ü3,4 = 
J 4,5 9.0 Hz, H-4a & H-4b), 4.41, 4.47, 4.48 (3 d, 3 H, J 12.5 Hz, 3 CHH in 
OBn), 4.49 (s, 1 H, H-lb), 4.53, 4.58, 4.64, 4.66, 4.73 (5 d, 5 H, J 12.5 Hz, 5 
CHH in OBn), 4.77 (s, 1 H, H-la), 4.78, 4.80 (2 d, 2 H, J 12.5 Hz, 2 CHH 
in OBn), 7.12 - 7.38 (m, 25 H, 5 CgHs), 10.20 (s, 2 H, 2 HOOC)
'^C NMR (125 MHz, CDCI3): 514.32 (2 CH3), 22.89 (2 CHz), 26.40 (2 
CHz), 29.65, 29.73, 29.83, 29.85, 29.89, 29.91 ( 2  CnHzz). 32.12 ( 2  CHz), 
45.67 (1 Cq), 68.53, 69.11, 69.25, 70.35, 71.94, 71.97, 72.54, 72.79, 73.21,
73.53, 74.11, 74.29, 74.56, 74.98, 75.06, 76.21, 77.93, 80.62, 100.97, 
101.99 (C-la, C-lb, J c , h  153.4, 156.7 Hz), 127.61, 127.64, 127.68, 127.82,
128.00, 128.03, 128.23, 128.33, 128.45, 128.53, 128.55, 128.57, 137.46,
138.07, 138.25, 138.71, 138.79 (5 Cq in PhCH), 172.02, 176.93 (2 HOOC).





To a solution of 16 (266.0 mg, 0.19 mmol, 1.0 eq.) and potassium 
fluoride (220.0 mg, 3.8 mmol, 20.0 eq.) in distilled DMF (5 ml) at r.t. was 
added dropwise benzylbromide (0.23 mL, 1.9 mmol, 10.0 eq.) which was 
pre-dissolved in 1 mL DMF with vigorous stirring. The mixture was kept 
stirring overnight until TLC check indicated complete reaction. DMF was
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removed by rotary evaporation under reduced pressure. To the residue was 
added 25 mL HzO and 25 ml DCM, extracted with DCM (3 x 25 mL), dried 
over NazSÜ4 , filtered, concentrated, purified by column chromatography 
with silica gel (eluent: Hexane / Ethyl acetate = 5 : 1 / 7 : 2 v/v) and 
concentrated under vacuum to provide pure compound 17 (202.0 mg, 67%) 
as a syrup.
RfO.55 (Hexane / EtOAc / MeOH / HOAc, 4 : 1 : 0.1 : 0.2 v/v).
[a]o^  ̂-76.5 (C O.ITCHCIg).
'H NMR (500 MHz, CDCI3): 5 0.88 (t, 6  H, J 3.5 Hz, 2 CH3), 1.25 (bs, 
52 H, 2 CnHze). 148 (bs, 4 H, 2 CHz), 2.77 (d, 1 H, J 2.5 Hz, 1 OH), 3.11 
(dd, 1 H, J 3,4 9.5, J 2,3 3.0 Hz, H-3b), 3.28 -  3.48 (m, 13 H), 3.69, 3.70 (2 d, 
2 H, J Z.3 3.0 Hz, H-2a & H-2b), 3.84 (d, 1 H, J 9.0 Hz), 4.00 (d, 1 H, J 9.0 
Hz), 4.15 (ddd, 1 H, J 4,5 =J 3,4 9.5, J o h , 42.5 Hz, H-4b), 4.33 (s, 1 H, H-lb), 
4.39 (d, 1 H, J 12.5 Hz, PhCHH), 4.40 (d, 1 H, J 9.5 Hz), 4.43 (d, 1 H, J 12.5 
Hz, PhCHH), 4.45 (d, 2 H, J 12.5 Hz, 2 PhCHH), 4.46 (s. 1 H, H-la), 4.49, 
4.57,4.64, 4.68, 4.71, 4.85, 5.00, 5.01, 5.10, 5.21 (10 d, 10 H, J 12.5 Hz, 10 
PhCHH), 7.14 -7.36 (m, 35 H, 7 CeHs),
’^C NMR (125 MHz, CDCI3): 514.34 ( 2  CH3), 22.94 ( 2  CHz), 26.46 (2 
CHz), 29.63, 29.79, 29.89, 29.92, 29.95, 29.97 ( 2  CnHzz), 32.16 ( 2  CHz),
45.46 (1 Cq), 61.86, 62.86, 64.06, 64.23, 67.35, 68.23, 68.58, 68.72, 69.53,
69.81, 70.73, 71.83, 72.53, 73.46, 73.47, 73.81, 74.41, 74.85, 75.18, 75.27, 
80.52,102.35,103.20 (C-la, C-lb, Jc,h153.9, 152.4 Hz), 127.50, 127.54,
127.56, 127.66, 127.83, 127.97, 128.03, 128.29, 128.39, 128.42, 128.46, 
128.54, 128.58, 128.59, 18.67, 128.71, 128.75, 128.88, 135.31, 135.52 (2 
Cq in COOBn), 138.29, 138.76, 138.92, 139.06, 139.08 (5 Cq in PhCHz), 
168.35, 168.36 (2 BnOOC).
Anal. Calcd for CgsHmOis: C, 75.06; H, 8.61. Found: C, 74.79; H, 8.67.
(3-benzyloxy-2,2-dihexadecyloxymethyl)-propyl(P-D-mannopyranosyl
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uronate)-(1-4)-(P-D-manno pyranosid)uronic acid (1).
O H
To a solution of 17 (117.0 mg, 0.075 mmol), dissolved in 60 mL freshly 
distilled THF, was carefully added palladium charcoal powder (Pd/C) (400 
mg). The solution was Hz saturated through for 2 mins. The reaction 
mixture was kept stirring for 2  hr at r.t. under Hz atmosphere established 
with a H z balloon, followed by addition of 15 mL H z O  and 0.1 mL EtzN and 
kept stirring overnight before a TLC check indicated complete conversion of 
the starting material to a lower single running spot. The reaction mixture 
was filtered and the filtrate [catalyst (Pd/C)] was washed with distilled 
THF-MeOH (1:1 v/v) several times. The final filtrate was concentrated 
under vaccum and followed by a freeze-drying from fresh 1,4-dioxane to 
provide a white powder 1 (46.0 mg, 64%).
RfO.52 (CHCI3 / MeOH / HzO / HOAc, 4 : 2 : 0 4 :  0.4 v/v).
[a]o^  ̂-116.0 (C 0.05, MeOH / CHCI3 = 2:1) .






To a solution of 14 (310.0 mg, 0.21 mmol, 1.0 eq.) and 
4-(dimethylamino)-pyridine (4-DMAP) (0.5 mg, 0.04 mmol, 0.2 eq.) in 5 mL 
dried pyridine at -25 °C was added benzoylcholoride (0.08 mL, 0.69 mmol,
3.3 eq.) which was pre-dissolved in 1 mL anhydrous DCM. The mixture was
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kept stirring for 2 hours at -25 °C until a TLC check indicating a complete 
reaction. Mixture was allowed to warm up to r.t. and then diluted in 20 mL 
EtOAC, followed by washing with 10 mL 4M HCL before being quenched 
with saturated aqueous NaHCOa, washed with ice-water (30 mL), extracted 
with EtOAC (3 x 30 mL), dried over Na2S0 4 , filtered, concentrated, purified 
by column chromatography on silica gel (eluent: hexane / ethyl acetate = 8  : 
1 / 5 : 1  v/v) and concentrated under vacuum to provide compound 18 (310 
mg, 94%) as a syrup.
RfO.72 (Hexane / EtOAc, 5 : 3 v/v).
[a]o^  ̂-58.7 (C 0.29, CHCI3).
^H NMR (500 MHz, CDCI3): 5 0.86 (t, 6  H, J  3.5 Hz, 2 CH3), 1.26 (bs, 
52 H, 2 C13H26). 1.46 (bs, 4 H, 2 CHz), 3.20 - 3.46 (m, 13 H), 3.59 (ddd, 1 H, 
J 3 ,4  = J 4 ,5  9.5, J o H ,4  3.5 Hz, H-4b), 3.68 (d, 1 H, J  9.5 Hz), 3.80, 3.92 (2 d,
2 H, J z,3  3.0 Hz, H-2a & H-2b), 3.96 -  4.01 (m, 2 H), 4.07 (d, 1 H, J 12.5 
Hz), 4.24 (dd, 1 H, J 3,4 = J 4,5 9.5 Hz, H-4a), 4.33 (d, 1 H, J 12.5 Hz, 
PhCHH), 4.36 (s, 1 H, H-lb), 4.37(d, 1 H, J 12.5 Hz, PhCHH), 4.43 (d, 2 H, 
J3.5 Hz), 4.44 (d, 1 H, J 12.5 Hz, PhCHH), 4.51, 4.57 (2d, 2 H, J 12.5 Hz, 2 
PhCHH), 4.58 (d, 2 H, J3.5 Hz), 4.60 (s, 1 H, H-la), 4.64, 4.68, 4.86, 4.75, 
4.84 (5 d, 5 H, J 12.5 Hz, 5 PhCHH), 7.19 - 7.39 (m, 29 H, 7 CgHs), 7.44, 
7.51 (2 t, 2 H, J 3,4 = J 4 ,5 7.5 Hz, 2 H-4 in Bz), 7.95, 8.04 (2 d, 2 H each, J 2,
3 = J 5 ,6 7.5 Hz, 2 H-2 & H- 6  in Bz).
'^ C  NMR (125 MHz, CDCI3): 514.35 (2 CH3), 22.92 (2 C H z ), 26.41 (2 
C H z ), 29.59, 29.75, 29.85, 29.88, 29.91, 29.93 ( 2  C n H z z ) ,  32.15 ( 2  C H z ),
45.41 (1 Cq), 61.64, 63.99, 64.22, 66.38, 69.84, 69.87, 70.14, 71.45, 71.79,
71.81, 72.01, 73.45, 73.57, 73.89, 74.49, 74.54, 74.65, 74.79, 75.64, 79.27,
81.67, 101.54, 102.40 (C-la, C-lb, J c ,h 156.4, 158.2 Hz), 127.47, 127.48, 
127.62, 127.75, 127.94, 128.05, 128.07, 128.17, 128.29, 128.31, 128.40,
128.46, 128.52, 128.61, 128.75 (35 C H  Arom),133.12, 133.24 (2 Cq in 
P h C O O ) ,  137.75, 138.60, 138.99, 139.05, 139.10 (5 Cq in P h C H z ) , 166.57, 
166.92 (2 P h C O O ) .
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To a solution of 9 (70.3 mg, 0.13 mmol, 1.8 eq.) in anhydrous DCM (10 
mL), conducted under Nz atmosphere, were added 4Â molecular sieves, 
1-benzenesulfinyl piperidine (BSP) (29.3 mg, 0.14 mmol, 2.0 eq.) and
2,6-di-terf-butyl-4 methylpyridine (DTBMP) (55.4 mg, 0.27 mmol, 3.6 eq ). 
The mixture was kept stirring for 0.5 hour at r.t.. Trifluoromethanesulfonic 
anhydride (T fz O )  (0.08 ml, 0.45 mmol, 1.65 eq.) was added dropwise at -60 
°C and 5 min later, a solution of 18 (110.0 mg, 0.07 mmol, 1.0 eq.) which 
was pre-dissolved in anhydrous DCM (3 ml), was added dropwise at -78 °C. 
The mixture was kept at -78 °C with vigorously stirring for 2 more hr and 
then allowed to be warmed up to r.t. before being quenched with saturated 
aqueous NaHCOa, washed with ice-water (15 mL), extracted with DCM (3 
X 15 mL), dried over NazS0 4 , filtered, concentrated, purified by column 
chromatography on silica gel (eluent: hexane / ethyl acetate = 5 :1  v/v) and 
concentrated under vacuum to provide a compound 19 (71.7 mg, 51%) as a 
syrup. After 11 mg starting material 18 was recovered, the yield was 
modified to 61%.
RfO.26 (Hexane / EtOAc / DCM, 5 : 0.7 : 0.5 v/v).
[a]o^  ̂-23.6 (C 0.41, MeOH / CHCI3 = 2:1) .
^H NMR (500 MHz, CDCI3): 5 0.88 (t, 6  H, J 3.5 Hz, 2 CH3),1.24 (bs, 52 
H, 2 CisHze), 1.46 (bs, 4 H, 2 C H z ), 2.97 (ddd, 1 H, Jac .sc  = J sc ,6c  9 5, J 5 ,6c' 
5.0 Hz, H-5c), 3.26 - 3.47 (m, 14 H), 3.54 - 3.61 (m, 4 H), 3.78, 3.86, 3.89 (3
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d, 3 H, J 2 ,3  3.0 Hz, H-2a, H-2b & H-2c), 3.89 (t, 1 H, Js, 4  = J 4,s 9.5 Hz, 
H-4b), 3.97 (d, 1 H, J 9.5 Hz), 3.98, 4.31 (2 d, 2 H, Ja,4 9.5 Hz, H-3a & H-3b),
4.04 (dd, 1 H, J 10.0 Hz), 4.16 -  4.21 (m, 2 H), 4.30 (d, 1 H, J 12.5 Hz, 1 
CHz in OBn), 4.36 (s, 1 H, H-lc), 4.37, 4.44 (2 d, 2 H, J 12.5 Hz, 2 CHH in 
OBn), 4.47 (s, 1 H, H-lb), 4.50, 4.54 (2d, 2 H, J 12.5 Hz, 2 CHH in OBn),
4.55 (d, 2 H, J 4.0 Hz), 4.56 (d, 1 H, J 12.5 Hz, 1 CHH in OBn), 4.63 (d, 1 H, 
J 12.5 Hz, 1 CHH in OBn), 4.64 (d, 2 H, J 4.0 Hz), 4.65, 4.69, 4.78 (3 d, 3 
H, J 12.5 Hz, 3 CHH in OBn), 4.78 (s, 1 H, H-la), 4.82,4.83, 4.87 (3 d, 3 H, 
J 12.5 Hz, 3 CHH in OBn), 5.48 (s, 1 H, CHPh), 7.04 - 7.43 (m, 39 H, 9 
CeHs), 7.47, 7.51 (2 t, 2 H, J 3 ,4  = J 4, s 7.5 Hz, 2 H-4 in Bz), 7.94, 8.04 (2d, 2 
H each, J z,3  = J 5,6 7.5 Hz, 2 H-2 & H- 6  in Bz).
'^C NMR (125 MHz, CDCI3): 514.38 (2 CH3), 22.93 (2 CHz), 26.42 (2 
CHz), 29.62, 29.78, 29.88, 29.91, 29.94, 29.96 ( 2  CnHzz), 32.15 ( 2  CHz),
45.41 (1 Cq), 63.68, 64.13, 67.57, 6 8 .6 6 , 69.85, 70.18, 71.80, 71.81, 72.10,
72.15, 72.46, 73.45, 73.48, 73.55, 73.95, 74.57, 74.81, 75.36, 75.53, 75.89, 
75.99, 77.20, 78.44, 78.56, 80.15, 101.51, 101.57, 102.11, 102.49 (C-la, 
C-lb, C-lc, PhCH, ■'Jc.H 153.1, 151.6, 152.3, 156.5 Hz), 126.3, 127.42, 
127.44, 127.47, 127.50, 127.66, 127.68, 127.71, 127.85, 128.06, 128.26, 
128.30, 128.33, 128.41, 128.48, 128.51,128.63, 129.89, 130.00 (10 Arom), 
133.26, 133.29 (2 Cq in PhCOO), 137.81, 138.56, 138.65, 138.78, 138.79, 
139.11, 139.12, 139.19 (7 Cq in PhCHz & 1 Cq in PhCH), 166.43, 166.52 (2 
PhCOO).
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OBn
To a solution of 19 (220.0 mg, 0.11 mmol, 1.0 eq.) and neopentyl glycol 
(75.0 mg, 0.72 mmol, 6.5 eq.) in anhydrous DCM (10 mL) at 35 °C, 
conducted under N2 atmosphere, was added CSA (37.5 mg, 0.16 mmol, 1.5 
eq.) with vigorous stirring. The mixture was left overnight until a TLC check 
indicated a complete reaction, followed by a work up: being quenched with 
saturated aqueous NaHCOs, washed with ice-water (15 mL), extracted with 
EtOAC (3 X 15 mL), dried over Na2S0 4 , filtered and concentrated. The 







The unpurified 20 (400 mg) was dissolved in solution of MeOH / DCM 
= 2 : 1 (30 ml) and MeONa was added dropwise until the pH of solution 
reached 10. The mxture is kept stirring for 17 hr followed by a TLC check 
indicated a complete reaction and then Resin-RCOOH was added until the 
pH=7, followed by filtration, purified by column chromatography on silica gel 
(eluent: H : E : DCM = 1 : 1 : 0 5  v/v) and concentrated under vacuum to 
provide compound 21 [155.0 mg, 83% (2 steps)] as a syrup.
Rf 0.38 (Hexane / EtOAc / DCM, 1 : 2 : 0 5  v/v).
^H NMR (500 MHz, CDCI3): ô 0.88 (t, 6  H, J 3.5 Hz, 2 CHs),1.25 (bs, 52 
H, 2 C13H26), 1.51 (bs, 4 H, 2 CH2), 2.30 (b, 4 H, 4 OH), 3.17 - 3.21 (m, 2 H), 
3.24 - 3.28 (2 dd, 2 H, J 3.0 Hz), 3.34 - 3.48 (m, 12 H), 3.50 (d, 2 H, J 9.5
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Hz), 3.62 - 3.66 (m, 2 H), 3.70, 3.72 (2 d, 2 H, J 4.0 Hz), 3.80 - 3.84 (m, 3 H),
3.86, 3.88 (2 d, 2 H, J 3.0 Hz), 3.96 (d, 1 H, J 9.5 Hz), 4.08, 4.13 (2 dd, 2 H, 
2  H-4), 4.34 (d, 1 H, J 12.5 Hz, 1 PhCHH), 4.37 (s, 1 H, H-lc), 4.44, 4.49 (2 
d, 2 H, J 12.5 Hz, 2 PhCHH), 4.50 (s, 1 H, H-lb), 4.50, 4.54, 4.55 (3 d, 3 H, 
J 12.5 Hz, 3 PhCHH), 4.59 (s, 1 H, H-la), 4.73, 4.74, 4.75, 4.79, 4.80, 4.83,
4.87, 4.89 ( 8  d, 8  H, J 12.5 Hz, 8  PhCHH], 7.24 - 7.40 (m, 35 H, 7 CgHs).
" c  NMR (125 MHz, CDCI3): 5 14.38 (2 CH3), 22.93 (2 CHz), 26.42 (2
CHz), 29.62, 29.78, 29.88, 29.91, 29.95, 29.96 ( 2  CnHza), 32.15 ( 2  CHz),
45.41 (1 Cq), 62.11, 62.23, 63.03, 67.56, 69.69, 69.73, 70.21, 71.55, 71.91,
72.45, 73.03, 73.54, 74.22, 74.50, 74.55, 74.84, 75.39, 75.70, 75.73, 75.78, 
76.65, 80.13, 80.30, 82.22, 101.20, 101.61, 102.58 (C-la, C-lb, C-lc, J c , h
155.0, 156.7, 158.3 Hz), 127.23, 127.45, 127.53, 127.63, 127.65, 127.73, 
127.75, 127.79, 127.81, 127.94, 128.20, 128.25, 128.37, 128.40, 128.47, 
128.49, 128.55, 128.56, 128.80, 137.88, 138.72, 138.78, 138.82, 138.85, 
138.90, 139.06 (7 Cq in Bn).






To a flask charged with 21 (155.0 mg, 0.09 mmol, 1.0 eq.),
2,2,6,6-tetramethyl -piperridinyloxy free radical (TEMPO) (11.5 mg, 0.074 
mmol, 0.82 eq.) and [bis(acetoxy)iodo]benzene (BAIB) (232.0 mg, 0.72 
mmol, 8.2 eq.) was added 4 ml DCM and 2 ml HzO with vigorous stirring. 
The reaction mixture was kept stirring for 4 hr until a TLC check indicated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
58
complete conversion of the starting material to a lower running spot. The 
mixture was quenched with aqueous NagSgOa (10% in HgO), washed with 
ice-water (10 ml), extracted with DCM (3x10 ml), dried through NazS0 4 , 
filtered, concentrated, purified by column chromatography on silica gel 
(eluent: Hexane / EtOAc / MeOH / HOAc = 6  : 1 : 0.1 : 0.2 v/v) and 
concentrated under vacuum to afford pure compound 22 (101.0 mg, 63%) 
as a syrup.
RfO.28 (Hexane / EtOAc / MeOH / HOAc, 3 :1 : 0.1 : 0.2 v/v).





To a solution of 22 (101.0 mg, 0.06 mmol, 1.0 eq.) and potassium 
fluoride (158.0 mg, 2.7 mmol, 45.0 eq.) in distilled DMF ( 8  mL) at r.t. was 
added dropwise benzylbromide (0.19 mL, 1.6 mmol, 27.0 eq.) which was 
pre-dissolved in 1 mL DMF with vigorous stirring. The mixture was kept 
stirring overnight until a TLC check indicated complete reaction. DMF was 
removed by rotary evaporation under reduced pressure. 10 mL H2O and 10 
mL DCM was added in reaction mixture. The mixture was taken up with 
DCM (3 X 20 mL), dried through Na2S0 4 , filtered, concentrated, purified by 
column chromatography on silica gel (eluent: hexane / ethyl acetate = 7 :1  
v/v) and concentrated under vacuum to provide pure compound 17 (74.0 
mg, 62%) as a syrup.
Rf0.70 (Hexane / EtOAc / MeOH / HOAc, 3 : 1 : 0.1 : 0.2 v/v).
[a]o^  ̂-39.6 (C 0 .6 6 , MeOH / CHCI3 = 2:1) .
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
59
NMR (500 MHz, CDCI3): 5 0.88 (t, 6  H, J 3.5 Hz, 2 CH3 ),1.25 (bs, 
52 H, 2 C13H26), 1.48 (bs, 4 H, 2 CH2), 2.74 (d, 1 H, OH), 3.03, 3.22 (dd, 2 H, 
J 3,4 9.5 Hz, J 2,3 3.0 Hz, H-3b & H-3c), 3.21 -3.42 (m, 11 H), 3.47 (dd, 2 H, 
J 3.0, J 9.5 Hz), 3.40 (d, 1 H, J 9.5 Hz), 3.61 (d, 1 H, J 3.5 Hz, H-2c), 3.62 (d, 
1 H, J 9.5 Hz), 3.68 (d, 2 H, J 2,3 3.0 Hz, 2 H-2), 3.75 (d, 1 H, J 9.5 Hz), 4.14 
(ddd, 1 H, J 3c,4c = J 4c, 5c 9.5 Hz, Ü4c,oh2 . 5  Hz, H-4c), 4.26 (dd, 1 H, J 9.5 Hz, 
H-4b), 4.28, 4.31 (2 s, 2 H, H-lb & H-lc), 4.34 (t, 1 H, J 9.5 Hz, H-4a), 4.38,
4.39, 4.40, 4.41 (4 d, 4 H, J 12.5 Hz, 4 PhCHH), 4.42 (s, 1 H, H-la), 4.43,
4.45, 4.46, 4.57, 4.67, 4.69, 4.71, 4.72, 4.75, 4.79, 4.85, 4.92, 4.98, 5.03,
5.07, 5.16 (16 d, 16 H, J 12.5 Hz, 16 PhCHH), 7.12 - 7.35 (m, 50 H, 10 
CeHs).
"C  NMR (125 MHz, CDCI3): 5 14.39 (2 CH3), 22.94 (2 CH2), 26.47 (2 
CH2), 29.62, 29.80, 29.89, 29.93, 29.95, 29.97 ( 2  C11H22), 32.18 ( 2  CHz),
45.46 (1 Cq), 66.97, 67.06, 67.14, 68.12, 69.68, 69.72, 69.75, 70.66, 71.51, 
71.71, 71.72, 72.51, 72.72, 73.36, 73.84, 74.62, 74.69, 74.93, 74.96, 75.08, 
75.17, 76.11, 77.25, 77.29, 79.75, 77.36, 79.50, 80.24, 102.25, 102.45, 
103.21 (C-la, C-lb, C-lc, J c , h  157.7, 155.6, 155.3 Hz), 127.49, 127.53,
127.56, 127.64, 127.82, 127.96, 128.02, 128.19, 128.29, 128.34, 128.40,
128.53, 128.64, 128.66, 128.70, 128.74, 128.78, 128.83, 128.86 (10 Arom],
135.39, 135.48, 135.49 (3 Cq in BnOOC), 138.26, 138.81, 139.10(2),
139.15, 139.20, 139.21 (7 Cq in PhCHzO), 168.12, 168.21, 169.27 (3 
BnOOC).




sid)uronic acid (2 ).
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To a solution of 23 (14.0 mg), dissolved in 32 mL freshly distilled THF, 
was carefully added palladium charcoal powder (Pd/C) (48.0 mg) and the 
solution was Hz bubbled through for 2 mins. The reaction mixture was kept 
stirring for 2 hr under Hz atmosphere established with a Hz balloon at r.t., 
followed by addition of 6 ml HzO and kept stirring overnight before a TLC 
check indicated complete conversion of the starting material to a lower 
single running spot. The reaction mixture was filtered and the filtrate 
[catalyst (Pd/C)] was washed with distilled THF-MeOH (1:1 v/v) several 
times. The final filtrate was concentrated under vaccum and followed by a 
freeze-drying from fresh 1,4-dioxane to provide a white powder 2 (7 mg, 
90%).
RfO.38 (iPrOH / HzO / NHs'HzO, 7 : 2 :  0.1 v/v).
[a]o^  ̂+47.3 (C 0.08, MeOH / CHCI3 = 2:1) .
MALDI-MS calcd for C55H100OZ2 1112.67 [M ]\ found 1136.05 [M+Naf,
1158.06 [M-H+2Na]T
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5. APPENDIX
and MS Spectra of Corresponding Compounds
1 NMR spectrum of 4 1
2 ^^0 NMR spectrum of 4 2
3 NMR spectrum of 5 3
4 NMR spectrum of 5 4
5 NMR spectrum of 6 5
6 ^ 0̂ NMR spectrum of 6 6
7 NMR spectrum of 10 7
8 NMR spectrum of 10 8
9 NMR spectrum of 11 9
10 NMR spectrum of 12 10
11 ^ 0̂ NMR spectrum of 12 11
12 NMR spectrum of 13 12
13 ^^0 NMR spectrum of 13 13
14 NMR spectrum of 14 14
15 NMR spectrum of 14 15
16 NMR spectrum of 15 16
17 ^ 0̂ NMR spectrum of 15 17
18 NMR spectrum of 16 18
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19 NMR spectrum of 16 19
20 NMR spectrum of 17 20
21 NMR spectrum of 17 21
22 NMR spectrum of 18 22
23 NMR spectrum of 18 23
24 NMR spectrum of 19 24
25 NMR spectrum of 19 25
26 NMR spectrum of 21 26
27 NMR spectrum of 21 27
28 NMR spectrum of 23 28
29 NMR spectrum of 23 29
30 MALDI-MS spectrum of 1 30
31 MALDI-MS spectrum of 1 31
32 MALDI-MS spectrum of 2 32
33 MALDI-MS spectrum of 2 33
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